JP2018503373A - がんの予後診断及び治療のための方法及び組成物 - Google Patents

がんの予後診断及び治療のための方法及び組成物 Download PDF

Info

Publication number
JP2018503373A
JP2018503373A JP2017534648A JP2017534648A JP2018503373A JP 2018503373 A JP2018503373 A JP 2018503373A JP 2017534648 A JP2017534648 A JP 2017534648A JP 2017534648 A JP2017534648 A JP 2017534648A JP 2018503373 A JP2018503373 A JP 2018503373A
Authority
JP
Japan
Prior art keywords
expression level
cancer
cells
determined
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017534648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503373A5 (enExample
Inventor
ルシアーナ モリネーロ，
ルシアーナ モリネーロ，
ヘグレ，プリディ
プリディ ヘグレ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2018503373A publication Critical patent/JP2018503373A/ja
Publication of JP2018503373A5 publication Critical patent/JP2018503373A5/ja
Priority to JP2021031306A priority Critical patent/JP7325463B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017534648A 2014-12-30 2015-12-29 がんの予後診断及び治療のための方法及び組成物 Pending JP2018503373A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021031306A JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098055P 2014-12-30 2014-12-30
US62/098,055 2014-12-30
PCT/US2015/067878 WO2016109546A2 (en) 2014-12-30 2015-12-29 Methods and compositions for prognosis and treatment of cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021031306A Division JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2018503373A true JP2018503373A (ja) 2018-02-08
JP2018503373A5 JP2018503373A5 (enExample) 2019-01-31

Family

ID=55315702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017534648A Pending JP2018503373A (ja) 2014-12-30 2015-12-29 がんの予後診断及び治療のための方法及び組成物
JP2021031306A Active JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021031306A Active JP7325463B2 (ja) 2014-12-30 2021-03-01 がんの予後診断及び治療のための方法及び組成物

Country Status (5)

Country Link
US (2) US11236394B2 (enExample)
EP (1) EP3240908A2 (enExample)
JP (2) JP2018503373A (enExample)
CN (1) CN107208138A (enExample)
WO (1) WO2016109546A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102084196B1 (ko) * 2018-08-29 2020-03-03 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
WO2021107452A1 (ko) * 2019-11-29 2021-06-03 의료법인 성광의료재단 면역 세포 치료제에 대한 치료 반응성 예측용 바이오마커
JP2021524744A (ja) * 2018-05-21 2021-09-16 ナノストリング テクノロジーズ，インコーポレイティド 分子遺伝子シグネチャーとその使用方法
JP2022511502A (ja) * 2018-12-05 2022-01-31 ジェネンテック， インコーポレイテッド がんの免疫療法のための診断方法及び診断用組成物
JP2022527972A (ja) * 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
JP2024502489A (ja) * 2021-01-12 2024-01-19 コーニンクレッカ フィリップス エヌ ヴェ 結腸直腸がん対象者の転帰の予測
WO2024225488A1 (ja) * 2023-04-27 2024-10-31 株式会社リプロセル 抗ｐｄ－１抗体療法に応答性である候補がん患者を同定する方法

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
JP7235508B2 (ja) * 2016-11-24 2023-03-08 第一三共株式会社 Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
EP3333268A1 (en) * 2016-12-09 2018-06-13 Institut Paoli Calmettes Biomarker panel for prognosis of bladder cancer
WO2018122249A1 (en) * 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
EP3580349A1 (en) * 2017-02-07 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Tim-3 for assessing the severity of cancer
CN106950371B (zh) * 2017-02-17 2019-03-08 张灏 Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途
EP3589754B1 (en) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
US10340030B2 (en) 2017-06-13 2019-07-02 Bostongene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
KR102348291B1 (ko) * 2017-06-14 2022-01-07 연세대학교 산학협력단 암 환자의 치료 반응성을 예측하는 방법
WO2018232142A1 (en) * 2017-06-14 2018-12-20 Icahn School Of Medicine At Mount Sinai Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
CN111164700B (zh) * 2017-07-14 2024-10-29 余因子基因组学公司 使用下一代测序的免疫-肿瘤学应用
JP7304558B2 (ja) * 2017-12-12 2023-07-07 地方独立行政法人神奈川県立病院機構 がん免疫療法の予後予測のためのバイオマーカー
CN108823309B (zh) * 2018-06-11 2021-11-30 北京大学人民医院 检测kiaa0125基因表达水平的物质在辅助鉴定急性淋巴细胞白血病中的应用
GB201810190D0 (en) * 2018-06-21 2018-08-08 Cancer Research Tech Ltd Prognostic and treatment response predictive method
EP3833323A4 (en) * 2018-08-08 2022-08-10 Cedars-Sinai Medical Center Compositions and methods for treating cancer and autoimmune diseases
US20210338727A1 (en) * 2018-09-13 2021-11-04 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
CA3131533A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN109880894A (zh) * 2019-03-05 2019-06-14 杭州西合森医学检验实验室有限公司 基于RNAseq的肿瘤免疫微环境预测模型的构建方法
EP3953712A1 (en) * 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
JP2022534967A (ja) * 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
EP3976040A1 (en) * 2019-06-01 2022-04-06 Ares Trading S.A. Pd-1 axis binding antagonist to treat cancer with genetic mutations in specific genes
KR102042710B1 (ko) * 2019-07-02 2019-11-08 의료법인 성광의료재단 면역체크 포인트와 관련된, 난소암 진단용 바이오마커
CN110804642B (zh) * 2019-09-10 2022-06-21 清华大学 Gpr174免疫学功能及其用途
US20210181200A1 (en) * 2019-12-17 2021-06-17 Women's College Hospital Ovarian cancer biomarker and methods of using same
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
CN111500733B (zh) * 2020-05-27 2022-03-08 中国人民解放军军事科学院军事医学研究院 外周血单核细胞中用于非小细胞肺癌早期诊断的分子标记物
AU2021293507A1 (en) 2020-06-18 2023-02-02 F. Hoffmann-La Roche Ag Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
KR102647295B1 (ko) * 2020-09-03 2024-03-14 한국과학기술연구원 암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도
WO2022053065A1 (zh) * 2020-09-14 2022-03-17 信达生物制药(苏州)有限公司 用于预测或评估肺癌患者的生物标志物、检测方法及应用
WO2022109607A2 (en) * 2020-11-19 2022-05-27 Tempus Labs, Inc. Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment
CN112530581B (zh) * 2020-12-03 2023-11-21 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用
CN112831562A (zh) * 2021-01-25 2021-05-25 浙江科技学院 一种用于预测肝癌患者切除术后复发风险的生物标志物组合、试剂盒
IL306090A (en) * 2021-03-25 2023-11-01 Oncxerna Therapeutics Inc Targeted cancer treatments
WO2022211620A1 (en) * 2021-04-01 2022-10-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Cd4/il-2 biomarker.
EP4370713A1 (en) 2021-07-15 2024-05-22 Vib Vzw Biomarkers predicting response of breast cancer to immunotherapy
JP7480754B2 (ja) 2021-07-19 2024-05-10 トヨタ自動車株式会社 蓄電装置
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
EP4526470A1 (en) * 2022-05-19 2025-03-26 Agendia N.V. Prediction of response to immune therapy in breast cancer patients
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
KR20240051492A (ko) * 2022-10-13 2024-04-22 주식회사 네오셀라 대식세포 분화 및 분포에 따른 면역세포 치료제의 치료 반응성 예측 방법
AU2024230918A1 (en) 2023-03-06 2025-10-16 Genentech, Inc. Prognostic and therapeutic methods for non-small cell lung cancer
WO2024234348A1 (en) * 2023-05-17 2024-11-21 Yanjun Wang Biomarker for immune checkpoint blockade therapy in nsclc
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505008A (ja) * 2009-09-18 2013-02-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 患者が免疫療法に対するレスポンダーかそうでなきかを同定するための方法
WO2014023706A1 (en) * 2012-08-06 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for screening patients with a cancer

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
EP0772609B1 (en) 1994-07-21 1999-02-24 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
TR199800012T1 (xx) 1995-07-06 1998-04-21 Novartis Ag Piroloprimidinler ve preparasyon i�in tatbikler.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
HUP0004286A3 (en) 1997-11-06 2002-01-28 American Cyanamid Co Madison Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps
JP3687900B2 (ja) 1998-11-19 2005-08-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー チロシンキナーゼの不可逆的阻害剤であるｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）キナゾリン−６−イル］アクリルアミド
JP5883384B2 (ja) * 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
WO2011040532A1 (ja) * 2009-10-02 2011-04-07 学校法人 久留米大学 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット
US9404926B2 (en) * 2010-01-29 2016-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2012016332A1 (en) * 2010-08-04 2012-02-09 Med Biogene Inc. Prognostic gene signatures for non-small cell lung cancer
KR20190133790A (ko) * 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
EP2615181A1 (en) * 2012-01-10 2013-07-17 Universite Joseph Fourier - Grenoble 1 Cyclon expression for the identification and control of cancer cells
SG10201700698WA (en) * 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2920325A2 (en) * 2012-11-15 2015-09-23 Bristol-Myers Squibb Company Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505008A (ja) * 2009-09-18 2013-02-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 患者が免疫療法に対するレスポンダーかそうでなきかを同定するための方法
WO2014023706A1 (en) * 2012-08-06 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for screening patients with a cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CLIN CANCER RES, vol. 15, no. 3, JPN6021029718, 2009, pages 1046 - 1051, ISSN: 0004562556 *
CLINICAL IMMUNOLOGY, vol. 134, JPN6021029717, 2010, pages 277 - 288, ISSN: 0004562557 *
GENE THERAPY, vol. 17, JPN6021029716, 2010, pages 972 - 979, ISSN: 0004562558 *
PLOS ONE, vol. vol.9, issue 2, JPN6022001755, February 2014 (2014-02-01), pages 89350 - 1, ISSN: 0004682948 *
SCIENCE, vol. 302, JPN6022001754, 2003, pages 1041 - 1043, ISSN: 0004682949 *
THE JOURNAL OF IMMUNOLOGY, vol. 177, JPN6022001753, 2006, pages 4330 - 4340, ISSN: 0004682950 *
ULTRA-LEAFTM PURIFIED ANTI-MOUSE CD8A ANTIBODY, JPN6022001752, 2014, ISSN: 0004682951 *
新たな癌免疫療法：制御性Ｔ細胞制御療法, vol. 101, no. 10, JPN6019045035, 2010, pages 207 - 214, ISSN: 0004682944 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021524744A (ja) * 2018-05-21 2021-09-16 ナノストリング テクノロジーズ，インコーポレイティド 分子遺伝子シグネチャーとその使用方法
JP2024053048A (ja) * 2018-05-21 2024-04-12 ナノストリング テクノロジーズ，インコーポレイティド 分子遺伝子シグネチャーとその使用方法
KR102084196B1 (ko) * 2018-08-29 2020-03-03 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
WO2020045996A1 (ko) * 2018-08-29 2020-03-05 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
US12480949B2 (en) 2018-08-29 2025-11-25 Industry-Academic Cooperation Foundation, Yonsei University Methods for treating non-small lung cancer and for preparing a sample
JP2022511502A (ja) * 2018-12-05 2022-01-31 ジェネンテック， インコーポレイテッド がんの免疫療法のための診断方法及び診断用組成物
JP7671248B2 (ja) 2018-12-05 2025-05-01 ジェネンテック， インコーポレイテッド がんの免疫療法のための診断方法及び診断用組成物
JP2022527972A (ja) * 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
WO2021107452A1 (ko) * 2019-11-29 2021-06-03 의료법인 성광의료재단 면역 세포 치료제에 대한 치료 반응성 예측용 바이오마커
JP2023504444A (ja) * 2019-11-29 2023-02-03 スンクワン メディカル ファウンデーション 免疫治療剤に係わる治療反応性予測用バイオマーカー
JP2024502489A (ja) * 2021-01-12 2024-01-19 コーニンクレッカ フィリップス エヌ ヴェ 結腸直腸がん対象者の転帰の予測
WO2024225488A1 (ja) * 2023-04-27 2024-10-31 株式会社リプロセル 抗ｐｄ－１抗体療法に応答性である候補がん患者を同定する方法

Also Published As

Publication number Publication date
EP3240908A2 (en) 2017-11-08
CN107208138A (zh) 2017-09-26
US12385098B2 (en) 2025-08-12
US20170260594A1 (en) 2017-09-14
WO2016109546A3 (en) 2016-09-01
US20220298576A1 (en) 2022-09-22
JP7325463B2 (ja) 2023-08-14
US11236394B2 (en) 2022-02-01
JP2021118684A (ja) 2021-08-12
WO2016109546A2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
JP7325463B2 (ja) がんの予後診断及び治療のための方法及び組成物
JP2024053048A (ja) 分子遺伝子シグネチャーとその使用方法
RU2710735C2 (ru) Композиции и способы лечения и диагностики резистентного к химиотерапии рака
TW201923089A (zh) 癌症之診斷及治療方法
JP7236164B2 (ja) 治療法に対する応答を予測する薬剤及び方法
US12183434B2 (en) Diagnostic and therapeutic methods for cancer
TW202027784A (zh) 腎癌之診斷及治療方法
TW202015730A (zh) 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
TW202011991A (zh) 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
CN113677994B (zh) 用于评估t细胞功能和预测对疗法的应答的方法和药剂
WO2020223233A1 (en) Prognostic and therapeutic methods for colorectal cancer
HK1244302A1 (en) Methods and compositions for prognosis and treatment of cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211213

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211214

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220121

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220125

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230131

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230411